Bloomberg reports LEO Pharma is pushing its planned IPO beyond 2026, despite having previously targeted a listing this year.
CEO Christophe Bourdon said the company is ready to go public, but its owners believe volatile market conditions do not support a listing now. No replacement date was announced.
The decision rests with LEO Foundation, which owns 80%, and Nordic Capital, which owns the remaining 20%. Bourdon described an IPO as a viable option, with timing dependent on business performance and investor appetite.
The Danish dermatology company says it is focused on steady growth and strengthening its business while it waits for more favorable conditions.
Sources:
Denmark's Leo Pharma Delays IPO Plans Beyond 2026, ...
LEO Pharma owners see market conditions as unsuitable for IPO, CEO says
Leo Pharma is delaying its IPO beyond 2026 on market volatility
Denmark’s Leo Pharma Delays IPO Plans Beyond 2026, CEO Says
Leo Pharma postpones its IPO plans until after 2026 amid market volatility | Daily Digest
LEO Pharma's IPO Timeline Looks Less Certain
LEO Pharma Sees Unfavorable Market for IPO, CEO Reveals
Leo Pharma is delaying plans for an IPO beyond 2026
Market turmoil threatens Leo Pharma's planned IPO ...
Denmark's Leo Pharma could postpone IPO amid market turmoil, Berlingske reports
Leo Pharma Eyes $800 Million Deal Push as IPO Plans ...